Literature DB >> 14531043

DAT imaging in drug-induced and psychogenic parkinsonism.

Eduardo Tolosa1, Miguel Coelho, Marisol Gallardo.   

Abstract

Parkinson's syndrome (PS) is frequently encountered in disorders associated with prominent degeneration of the nigrostriatal pathway as in Parkinson's disease, multisystem atrophy, and progressive supranuclear palsy (presynaptic PS). Drug-induced parkinsonism, a common, underdiagnosed health problem and psychogenic parkinsonism are causes of Parkinson's syndrome which, evidence suggests, occurs without degeneration of nigrostriatal structures. We review clinical features and results of DAT imaging in drug-induced parkinsonism and psychogenic parkinsonism. These two conditions normally give normal striatal DAT imaging results; an abnormal result in either case could exclude both conditions, corroborating a diagnosis of organic parkinsonism in uncertain cases. Copyright 2003 Movement Disorder Society

Entities:  

Mesh:

Year:  2003        PMID: 14531043     DOI: 10.1002/mds.10575

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  27 in total

1.  Risk for antipsychotic-induced extrapyramidal symptoms: influence of family history and genetic susceptibility.

Authors:  Meike Kasten; Norbert Brüggemann; Inke R König; Katja Doerry; Susanne Steinlechner; Liv Wenzel; Katja Lohmann; Christine Klein; Rebekka Lencer
Journal:  Psychopharmacology (Berl)       Date:  2010-11-12       Impact factor: 4.530

2.  Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait.

Authors:  Jose J Mateos; Francisco Lomeña; Eduard Parellada; Font Mireia; Emili Fernandez-Egea; Javier Pavia; Alberto Prats; Francisca Pons; Miquel Bernardo
Journal:  Psychopharmacology (Berl)       Date:  2006-09-22       Impact factor: 4.530

3.  Reply to Comment on: Dopamine Transporter (DaT) Scan Utilization in a Movement Disorder Center.

Authors:  Srivadee Oravivattanakul; Lucas Benchaya; Anwar Ahmed; Ilia Itin; Scott Cooper; Michal Gostkowski; Joseph Rudolph; Kristin Appleby; Patrick Sweeney; Hubert H Fernandez; Guiyun Wu
Journal:  Mov Disord Clin Pract       Date:  2016-07-28

4.  Clinical features of drug-induced parkinsonism based on [18F] FP-CIT positron emission tomography.

Authors:  Hae-Won Shin; Jae Seung Kim; Minyoung Oh; Sooyeoun You; Young Jin Kim; Juyeon Kim; Mi-Jung Kim; Sun Ju Chung
Journal:  Neurol Sci       Date:  2014-09-18       Impact factor: 3.307

Review 5.  Psychogenic parkinsonism.

Authors:  Mark Hallett
Journal:  J Neurol Sci       Date:  2011-04-01       Impact factor: 3.181

6.  Cardiac 123I-MIBG scintigraphy in patients with drug induced parkinsonism.

Authors:  P H Lee; J S Kim; D H Shin; S-N Yoon; K Huh
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-08-15       Impact factor: 10.154

7.  Microstructural white matter alterations in patients with drug induced parkinsonism.

Authors:  Yoonju Lee; Yong Ho Choi; Jae Jung Lee; Hye Sun Lee; Young H Sohn; Jong-Min Lee; Phil Hyu Lee
Journal:  Hum Brain Mapp       Date:  2017-09-12       Impact factor: 5.038

8.  Clinical Implications of Cardiac-MIBG SPECT in the Differentiation of Parkinsonian Syndromes.

Authors:  Dong Hoon Shin; Phil Hyu Lee; Oh Young Bang; In Soo Joo; Kyoon Huh
Journal:  J Clin Neurol       Date:  2006-03-20       Impact factor: 3.077

9.  The sensitivity and specificity of F-DOPA PET in a movement disorder clinic.

Authors:  Nevein Ibrahim; Joanna Kusmirek; Aaron F Struck; John M Floberg; Scott B Perlman; Catherine Gallagher; Lance T Hall
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-01-28

10.  Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson's disease.

Authors:  Francisco J Diaz-Corrales; Salome Sanz-Viedma; David Garcia-Solis; Teresa Escobar-Delgado; Pablo Mir
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10-28       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.